KR20240126856A - 렌티바이러스 벡터 - Google Patents
렌티바이러스 벡터 Download PDFInfo
- Publication number
- KR20240126856A KR20240126856A KR1020247015385A KR20247015385A KR20240126856A KR 20240126856 A KR20240126856 A KR 20240126856A KR 1020247015385 A KR1020247015385 A KR 1020247015385A KR 20247015385 A KR20247015385 A KR 20247015385A KR 20240126856 A KR20240126856 A KR 20240126856A
- Authority
- KR
- South Korea
- Prior art keywords
- sequence
- ltr
- modified
- expression cassette
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 title claims abstract description 885
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 455
- 239000002773 nucleotide Substances 0.000 claims abstract description 452
- 238000004519 manufacturing process Methods 0.000 claims abstract description 185
- 230000002452 interceptive effect Effects 0.000 claims abstract description 119
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 43
- 108700019146 Transgenes Proteins 0.000 claims description 706
- 230000014509 gene expression Effects 0.000 claims description 673
- 230000008488 polyadenylation Effects 0.000 claims description 287
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 273
- 108020004999 messenger RNA Proteins 0.000 claims description 236
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 188
- 101000723815 Homo sapiens Zinc finger CCHC domain-containing protein 14 Proteins 0.000 claims description 160
- 102100028477 Zinc finger CCHC domain-containing protein 14 Human genes 0.000 claims description 159
- 230000027455 binding Effects 0.000 claims description 139
- 239000002679 microRNA Substances 0.000 claims description 123
- 238000003776 cleavage reaction Methods 0.000 claims description 121
- 230000007017 scission Effects 0.000 claims description 107
- 230000001177 retroviral effect Effects 0.000 claims description 85
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 77
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 76
- 108091070501 miRNA Proteins 0.000 claims description 69
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 65
- 238000011144 upstream manufacturing Methods 0.000 claims description 63
- 238000004806 packaging method and process Methods 0.000 claims description 44
- 150000007523 nucleic acids Chemical group 0.000 claims description 43
- 239000013603 viral vector Substances 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 35
- 230000000692 anti-sense effect Effects 0.000 claims description 34
- 230000014759 maintenance of location Effects 0.000 claims description 34
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 30
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 25
- 230000001086 cytosolic effect Effects 0.000 claims description 23
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 20
- 108020004459 Small interfering RNA Proteins 0.000 claims description 20
- 239000004055 small Interfering RNA Substances 0.000 claims description 20
- 108091026838 U1 spliceosomal RNA Proteins 0.000 claims description 19
- 238000003860 storage Methods 0.000 claims description 17
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 16
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 15
- 108700026244 Open Reading Frames Proteins 0.000 claims description 14
- 230000001124 posttranscriptional effect Effects 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 13
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 10
- 108091081021 Sense strand Proteins 0.000 claims description 9
- 108091027981 Response element Proteins 0.000 claims description 8
- 230000003278 mimic effect Effects 0.000 claims description 8
- 101710109819 Transcription attenuation protein MtrB Proteins 0.000 claims description 6
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 5
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 claims description 4
- 230000019113 chromatin silencing Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000012033 transcriptional gene silencing Methods 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 2
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 2
- 241000713325 Visna/maedi virus Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 241001446316 Bohle iridovirus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 235
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 117
- 239000005090 green fluorescent protein Substances 0.000 description 91
- 108700004025 env Genes Proteins 0.000 description 67
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 66
- 108090000623 proteins and genes Proteins 0.000 description 61
- 108700011259 MicroRNAs Proteins 0.000 description 53
- 230000000694 effects Effects 0.000 description 49
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 48
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 48
- 230000001464 adherent effect Effects 0.000 description 45
- 230000002103 transcriptional effect Effects 0.000 description 44
- 238000000684 flow cytometry Methods 0.000 description 39
- 239000000725 suspension Substances 0.000 description 38
- 108700009124 Transcription Initiation Site Proteins 0.000 description 37
- 108091062157 Cis-regulatory element Proteins 0.000 description 36
- 230000010354 integration Effects 0.000 description 36
- 238000010839 reverse transcription Methods 0.000 description 36
- 108091092195 Intron Proteins 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 34
- 230000001976 improved effect Effects 0.000 description 31
- 102000053642 Catalytic RNA Human genes 0.000 description 28
- 108090000994 Catalytic RNA Proteins 0.000 description 28
- 108091092562 ribozyme Proteins 0.000 description 28
- 230000001413 cellular effect Effects 0.000 description 25
- 241000714474 Rous sarcoma virus Species 0.000 description 24
- 239000000370 acceptor Substances 0.000 description 24
- 230000035772 mutation Effects 0.000 description 24
- 239000002924 silencing RNA Substances 0.000 description 24
- 238000011529 RT qPCR Methods 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 22
- 238000010361 transduction Methods 0.000 description 22
- 230000014616 translation Effects 0.000 description 22
- 239000005089 Luciferase Substances 0.000 description 21
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 239000003623 enhancer Substances 0.000 description 21
- 230000009368 gene silencing by RNA Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 230000035897 transcription Effects 0.000 description 21
- 238000013518 transcription Methods 0.000 description 21
- 241000701022 Cytomegalovirus Species 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 20
- 238000012217 deletion Methods 0.000 description 19
- 230000037430 deletion Effects 0.000 description 19
- 238000010804 cDNA synthesis Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 108020004635 Complementary DNA Proteins 0.000 description 16
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 16
- 230000007246 mechanism Effects 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 15
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 235000011475 lollipops Nutrition 0.000 description 15
- 238000013519 translation Methods 0.000 description 15
- 108091035707 Consensus sequence Proteins 0.000 description 14
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 230000001594 aberrant effect Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 239000013615 primer Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000013715 transcription antitermination Effects 0.000 description 11
- 230000005030 transcription termination Effects 0.000 description 11
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 10
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 10
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000003306 harvesting Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 230000035892 strand transfer Effects 0.000 description 10
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000007115 recruitment Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 102100024768 ATP-dependent RNA helicase DDX50 Human genes 0.000 description 7
- 101000830424 Homo sapiens ATP-dependent RNA helicase DDX50 Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 108020005176 AU Rich Elements Proteins 0.000 description 6
- 108010076130 Cleavage And Polyadenylation Specificity Factor Proteins 0.000 description 6
- 102000011591 Cleavage And Polyadenylation Specificity Factor Human genes 0.000 description 6
- 108020004566 Transfer RNA Proteins 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012761 co-transfection Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- CPXIIHVUIFVTLA-YOCMHDSMSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=N)=C2N=C1.C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O CPXIIHVUIFVTLA-YOCMHDSMSA-N 0.000 description 4
- -1 CSTF Proteins 0.000 description 4
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 101150017737 HSPB3 gene Proteins 0.000 description 4
- 102100039168 Heat shock protein beta-3 Human genes 0.000 description 4
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 4
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 4
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 102100023132 Transcription factor Jun Human genes 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 108091007428 primary miRNA Proteins 0.000 description 4
- 239000013608 rAAV vector Substances 0.000 description 4
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 230000010464 virion assembly Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 102100037935 Polyubiquitin-C Human genes 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 102100039485 Symplekin Human genes 0.000 description 3
- 101710138921 Symplekin Proteins 0.000 description 3
- 230000006154 adenylylation Effects 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 108091023663 let-7 stem-loop Proteins 0.000 description 3
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 3
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000030147 nuclear export Effects 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 2
- 102100030871 Cleavage and polyadenylation specificity factor subunit 5 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 101000727072 Homo sapiens Cleavage and polyadenylation specificity factor subunit 5 Proteins 0.000 description 2
- 101000610204 Homo sapiens Poly(A) polymerase alpha Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 108091007767 MALAT1 Proteins 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 102100040155 Poly(A) polymerase alpha Human genes 0.000 description 2
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 description 2
- 101710150344 Protein Rev Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 241000242680 Schistosoma mansoni Species 0.000 description 2
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 2
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 238000013400 design of experiment Methods 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108091053735 lin-4 stem-loop Proteins 0.000 description 2
- 108091032363 lin-4-1 stem-loop Proteins 0.000 description 2
- 108091028008 lin-4-2 stem-loop Proteins 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 102000028499 poly(A) binding Human genes 0.000 description 2
- 108091023021 poly(A) binding Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 description 2
- 238000010379 pull-down assay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100084595 Caenorhabditis elegans pam-1 gene Proteins 0.000 description 1
- 102100030954 Cleavage and polyadenylation specificity factor subunit 3 Human genes 0.000 description 1
- 102100026529 Cleavage and polyadenylation specificity factor subunit 6 Human genes 0.000 description 1
- 102100026421 Cleavage and polyadenylation specificity factor subunit 7 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 101000727101 Homo sapiens Cleavage and polyadenylation specificity factor subunit 3 Proteins 0.000 description 1
- 101000855366 Homo sapiens Cleavage and polyadenylation specificity factor subunit 6 Proteins 0.000 description 1
- 101000855404 Homo sapiens Cleavage and polyadenylation specificity factor subunit 7 Proteins 0.000 description 1
- 101000610208 Homo sapiens Poly(A) polymerase gamma Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 102100040153 Poly(A) polymerase gamma Human genes 0.000 description 1
- 101710081489 Protein argonaute Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 230000014632 RNA localization Effects 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091026828 U2 spliceosomal RNA Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006743 cytoplasmic accumulation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 238000002898 library design Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 1
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 1
- 108091049679 miR-20a stem-loop Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000006849 nucleocytoplasmic transport Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2114529.7 | 2021-10-12 | ||
| GBGB2114529.7A GB202114529D0 (en) | 2021-10-12 | 2021-10-12 | Lentiviral vectors |
| PCT/GB2022/052586 WO2023062367A1 (en) | 2021-10-12 | 2022-10-12 | Lentiviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240126856A true KR20240126856A (ko) | 2024-08-21 |
Family
ID=78595195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247015385A Pending KR20240126856A (ko) | 2021-10-12 | 2022-10-12 | 렌티바이러스 벡터 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250034589A1 (enExample) |
| EP (2) | EP4530355A3 (enExample) |
| JP (1) | JP2024536908A (enExample) |
| KR (1) | KR20240126856A (enExample) |
| CN (1) | CN118234868A (enExample) |
| GB (1) | GB202114529D0 (enExample) |
| WO (1) | WO2023062367A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4589007A1 (en) * | 2024-01-17 | 2025-07-23 | Revvity Gene Delivery GmbH | Production of viral vectors |
| WO2026038929A1 (ko) * | 2024-08-16 | 2026-02-19 | 서울대학교산학협력단 | Rna 안정성 또는 mrna 번역 증가용 신규 조절 엘리먼트 및 이의 용도 |
| WO2026085234A1 (en) * | 2024-10-18 | 2026-04-23 | Modernatx, Inc. | 3' untranslated region sequences for extending messenger ribonucleic acids half-life |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5512421A (en) | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| CZ297278B6 (cs) | 1996-08-07 | 2006-10-11 | Darwin Discovery Limited | Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| WO1999032646A1 (en) | 1997-12-22 | 1999-07-01 | Oxford Biomedica (Uk) Limited | Equine infectious anaemia virus (eiav) based |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB9904905D0 (en) | 1999-03-03 | 1999-04-28 | Oxford Biomedica Ltd | Cells |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| WO2001085974A2 (en) * | 2000-05-12 | 2001-11-15 | University Of Southern California | Retroviral vectors comprising an enhanced 3' transcription termination structure |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| DK2348119T3 (en) | 2002-02-01 | 2017-08-21 | Oxford Biomedica (Uk) Ltd | Polycistronic lentiviral vector |
| AU2003260769A1 (en) | 2002-09-03 | 2004-03-29 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
| US20060019393A1 (en) * | 2003-12-04 | 2006-01-26 | Cannon Paula M | Minimal lentiviral vector system |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| GB0526210D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2009153563A1 (en) | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| US20110294114A1 (en) | 2009-12-04 | 2011-12-01 | Cincinnati Children's Hospital Medical Center | Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| FI3633040T3 (fi) | 2017-12-22 | 2023-08-03 | Oxford Biomedica Ltd | Retrovirusvektori |
| EP4004204A1 (en) | 2019-07-23 | 2022-06-01 | Oxford BioMedica (UK) Limited | Enhancing production of lentiviral vectors |
| WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
| US20240052366A1 (en) | 2020-02-13 | 2024-02-15 | Oxford Biomedica (Uk) Limited | Production of Lentiviral Vectors |
| WO2021181108A1 (en) | 2020-03-13 | 2021-09-16 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
| GB202114532D0 (en) * | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
-
2021
- 2021-10-12 GB GBGB2114529.7A patent/GB202114529D0/en not_active Ceased
-
2022
- 2022-10-12 CN CN202280075601.1A patent/CN118234868A/zh active Pending
- 2022-10-12 KR KR1020247015385A patent/KR20240126856A/ko active Pending
- 2022-10-12 EP EP24214942.5A patent/EP4530355A3/en active Pending
- 2022-10-12 EP EP22790351.5A patent/EP4416296A1/en not_active Withdrawn
- 2022-10-12 WO PCT/GB2022/052586 patent/WO2023062367A1/en not_active Ceased
- 2022-10-12 US US18/699,885 patent/US20250034589A1/en active Pending
- 2022-10-12 JP JP2024521765A patent/JP2024536908A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250034589A1 (en) | 2025-01-30 |
| JP2024536908A (ja) | 2024-10-08 |
| WO2023062367A1 (en) | 2023-04-20 |
| EP4416296A1 (en) | 2024-08-21 |
| GB202114529D0 (en) | 2021-11-24 |
| CN118234868A (zh) | 2024-06-21 |
| EP4530355A2 (en) | 2025-04-02 |
| EP4530355A3 (en) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7787064B2 (ja) | レンチウイルスベクターの製造の増強 | |
| US12312592B2 (en) | Retroviral vector | |
| JP7759318B2 (ja) | 産生系 | |
| US20240052366A1 (en) | Production of Lentiviral Vectors | |
| US20230118587A1 (en) | Lentiviral Vectors | |
| US20210079360A1 (en) | Viral vector production system | |
| EP4530355A2 (en) | Lentiviral vectors | |
| WO2023062359A2 (en) | Novel viral regulatory elements | |
| WO2023062363A1 (en) | Lentiviral vectors | |
| WO2023062365A2 (en) | Lentiviral vectors | |
| US20230183742A1 (en) | Viral Vector Production | |
| WO2023062366A1 (en) | Retroviral vectors | |
| EP4573112A1 (en) | Envelope proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240508 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |